Conmed (CNMD) Net Income towards Common Stockholders (2010 - 2026)

Conmed's Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at $13.8 million for Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 129.09% year-over-year to $13.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.5 million (down 103.82% YoY) and the FY2025 annual result came in at -$12.3 million, down 109.31% from the prior year.
• Net Income towards Common Stockholders was $13.8 million for Q1 2026 at Conmed, up from -$42.6 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $95.3 million in Q4 2022 and bottomed at -$168.3 million in Q2 2022.
• A 5-year average of $6.7 million and a median of $15.0 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders tumbled 1366.3% — and 2024, when it surged 983.51%.
• Conmed's Net Income towards Common Stockholders stood at $95.3 million in 2022, then slumped by 141.17% to -$39.2 million in 2023, then surged by 186.03% to $33.8 million in 2024, then plunged by 226.35% to -$42.6 million in 2025, then surged by 132.42% to $13.8 million in 2026.
• Business Quant data shows CNMD's Net Income towards Common Stockholders at $13.8 million in Q1 2026, -$42.6 million in Q4 2025, and $2.9 million in Q3 2025.